Abstract
Background: Heterocyclic system is a common structure feature of widely used drugs such as anticancer, anticonvulsant, antieplipeptic, and antiparastic agents.
Methods: Structure-based drug design and Glide docking studies were employed to rationalize the toxicity of a new series of thiosemicarbazone-based indole derivatives against human colon carcinoma (HCT116) cell line.
Results: Glide docking studies showed that the verified compounds fit PI3Kα kinase catalytic site and form H-bonding with K802, Y836, V851, S854, Q859, S919, and D933. The pharmacophore modeling of PI3Kα active inhibitors displayed that verified compounds matched four out of five functionalities of PI3Kα inhibitors.
Conclusion: Our findings suggest that further optimization of the core structure of this series would be beneficial for colon cancer treatment.
Keywords: PI3Kα, glide docking, pharmacophore screening, HCT-116, thiosemicarbazone-based indoles, DNA, RNA.
Letters in Drug Design & Discovery
Title:Molecular Docking Studies of Novel Thiosemicarbazone-based Indoles as Potential PI3Kα Inhibitors
Volume: 14 Issue: 11
Author(s): Dima A. Sabbah*Kamal Sweidan
Affiliation:
- Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, P.O. Box 130, Amman 11733,Jordan
Keywords: PI3Kα, glide docking, pharmacophore screening, HCT-116, thiosemicarbazone-based indoles, DNA, RNA.
Abstract: Background: Heterocyclic system is a common structure feature of widely used drugs such as anticancer, anticonvulsant, antieplipeptic, and antiparastic agents.
Methods: Structure-based drug design and Glide docking studies were employed to rationalize the toxicity of a new series of thiosemicarbazone-based indole derivatives against human colon carcinoma (HCT116) cell line.
Results: Glide docking studies showed that the verified compounds fit PI3Kα kinase catalytic site and form H-bonding with K802, Y836, V851, S854, Q859, S919, and D933. The pharmacophore modeling of PI3Kα active inhibitors displayed that verified compounds matched four out of five functionalities of PI3Kα inhibitors.
Conclusion: Our findings suggest that further optimization of the core structure of this series would be beneficial for colon cancer treatment.
Export Options
About this article
Cite this article as:
Sabbah A. Dima *, Sweidan Kamal , Molecular Docking Studies of Novel Thiosemicarbazone-based Indoles as Potential PI3Kα Inhibitors, Letters in Drug Design & Discovery 2017; 14 (11) . https://dx.doi.org/10.2174/1570180814666170619112647
DOI https://dx.doi.org/10.2174/1570180814666170619112647 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Fatty Acids in the Activity of the Uncoupling Proteins
Current Chemical Biology Modifications of Cell Signalling and Redox Balance by Targeting Protein Acetylation Using Natural and Engineered Molecules: Implications in Cancer Therapy
Current Topics in Medicinal Chemistry Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer
Anti-Cancer Agents in Medicinal Chemistry Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease
Current Pharmaceutical Design Nimesulide is a Selective COX-2 Inhibitory, Atypical Non-Steroidal Anti-Inflammatory Drug
Current Medicinal Chemistry Physiological Functions of Heat Shock Proteins
Current Protein & Peptide Science Metastasis-Initiating Cells in Renal Cancer
Current Signal Transduction Therapy Meet Our Section Editor
Reviews on Recent Clinical Trials Recent Developments in Patents Targeting Toll-Like Receptor Genes
Recent Patents on DNA & Gene Sequences Tumor Targeted Therapies: Strategies for Killing Cancer but not Normal Cells
Current Cancer Therapy Reviews Intelligent Drug Delivery Systems Based on Modified Chitosan Nanoparticles
Letters in Organic Chemistry Recent Progress in the Development of Small Molecule c-Met Inhibitors
Current Topics in Medicinal Chemistry In Silico Prediction of Novel Inhibitors of the DNA Binding Activity of FoxG1
Medicinal Chemistry PPARs as Drug Targets to Modulate Inflammatory Responses?
Current Drug Targets - Inflammation & Allergy Recent Development and SAR Analysis of Colchicine Binding Site Inhibitors
Mini-Reviews in Medicinal Chemistry Gastric Carcinoma at the Era of Targeted Therapies
Current Drug Targets Interrelationships Among Gut Microbiota and Host: Paradigms, Role in Neurodegenerative Diseases and Future Prospects
CNS & Neurological Disorders - Drug Targets AKT/GSK-3 Pathway Targeting; Botanicals and Bioactive Compounds with Anticancer Activities
Current Pharmaceutical Design Metastasis Suppressors: Basic and Translational Advances
Current Pharmaceutical Biotechnology